Version history

{
  "content_md": "# Progranulin Protein (PGRN)\n\n<table class=\"infobox infobox-protein\">\n  <tr>\n    <th class=\"infobox-header\" colspan=\"2\">Progranulin (PGRN)</th>\n  </tr>\n  <tr>\n    <td class=\"label\">Gene</td>\n    <td>[GRN](/genes/grn)</td>\n  </tr>\n  <tr>\n    <td class=\"label\">UniProt</td>\n    <td><a href=\"https://www.uniprot.org/uniprot/P28799\" target=\"_blank\">P28799</a></td>\n  </tr>\n  <tr>\n    <td class=\"label\">Protein Name</td>\n    <td>Progranulin</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Molecular Weight</td>\n    <td>63.5 kDa (full-length); secreted fragments: 6-25 kDa</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Length</td>\n    <td>593 amino acids</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Localization</td>\n    <td>Secreted, Lysosomes, Cytoplasm</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Expression</td>\n    <td>Neurons, Microglia, Macrophages, Epithelial cells</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Associated Diseases</td>\n    <td>[Frontotemporal Dementia](/diseases/frontotemporal-dementia), [Amyotrophic Lateral Sclerosis](/diseases/als), [Alzheimer's Disease](/diseases/alzheimers-disease)</td>\n  </tr>\n</table>\n\n# Progranulin Protein (PGRN)\n\n## Overview\n\n\n```mermaid\nflowchart TD\n    PROGRANULIN_PROTEIN[\"PROGRANULIN_PROTEIN\"]\n    PROGRANULIN_PROTEIN_1[\"PGRN\"]\n    PROGRANULIN_PROTEIN -->|\"related to\"| PROGRANULIN_PROTEIN_1\n    style PROGRANULIN_PROTEIN_1 fill:#81c784,stroke:#333,color:#000\n    PROGRANULIN_PROTEIN_2[\"table\"]\n    PROGRANULIN_PROTEIN -->|\"related to\"| PROGRANULIN_PROTEIN_2\n    style PROGRANULIN_PROTEIN_2 fill:#81c784,stroke:#333,color:#000\n    PROGRANULIN_PROTEIN_3[\"class\"]\n    PROGRANULIN_PROTEIN -->|\"related to\"| PROGRANULIN_PROTEIN_3\n    style PROGRANULIN_PROTEIN_3 fill:#81c784,stroke:#333,color:#000\n    style PROGRANULIN_PROTEIN fill:#4fc3f7,stroke:#333,color:#000\n```\n\n**Progranulin (PGRN)** is a secreted glycoprotein encoded by the [GRN](/genes/grn) gene that functions as a crucial regulator of neuronal survival, lysosomal function, immune response, and synaptic plasticity. The protein has a molecular weight of 63.5 kDa in its full-length form and is proteolytically processed into smaller granulins (6-25 kDa) that have distinct biological activities[@baker2006]. Progranulin is localized to multiple cellular compartments including the secretory pathway, lysosomes, and cytoplasm, where it participates in diverse cellular processes[@chintapaludi2021].\n\nHaploinsufficiency caused by [GRN](/genes/grn) mutations is one of the most common genetic causes of [frontotemporal dementia (FTD)](/diseases/frontotemporal-dementia), accounting for approximately 5-10% of all FTD cases and up to 20% of familial FTD[@gtzl2020]. Additionally, GRN mutations have been implicated in [amyotrophic lateral sclerosis (ALS)](/diseases/als) and may modify [Alzheimer's disease (AD)](/diseases/alzheimers-disease) risk. The discovery that GRN mutations cause FTD through a haploinsufficiency mechanism, resulting in approximately 50% reduction in functional protein levels, has driven significant therapeutic development efforts focused on protein replacement or upregulation[@arrant2023].\n\n---\n\n## Structure and Biochemistry\n\n### Primary Structure\n\nProgranulin is a 593-amino acid secreted glycoprotein with a molecular weight of 63.5 kDa. The protein contains multiple functional domains:\n\n| Domain | Position | Description |\n|--------|----------|-------------|\n| Signal peptide | 1-18 | Directs secretion via secretory pathway |\n| Granulin repeats | 19-564 | 7.5 tandem repeats of ~60-80 aa each |\n| Cysteine-rich regions | Between repeats | Provide structural stability |\n| N-glycosylation sites | Multiple | Affect secretion and stability |\n\n### Granulin Repeats\n\nThe hallmark of progranulin is its series of granulin repeats:\n- **P-granulin (full-length)**: Contains all 7.5 repeats\n- **Granulin A-G**: Individual repeats released by proteolytic cleavage\n- **Paragranulin**: Contains only the first four repeats\n\nEach granulin repeat contains:\n- 12 conserved cysteine residues forming disulfide bonds\n- Characteristic \"Gliadin\" fold\n- Protease resistance due to dense disulfide bonding\n\n### Proteolytic Processing\n\nProgranulin is cleaved by multiple proteases:\n\n| Protease | Cleavage Site | Result |\n|----------|---------------|--------|\n| Elastase | Between repeats | Granulin fragments |\n| Matrix metalloproteinases (MMP-3, MMP-9) | Variable | Multiple fragments |\n| Cathepsin D | Within repeats | Smaller fragments |\n| ADAMTS-4 | N-terminal | Truncated forms |\n\nThe cleavage products (granulins) have distinct biological activities:\n- Some granulins are neurotrophic\n- Others may have inflammatory functions\n- Balance between full-length PGRN and fragments is biologically important\n\n### Post-Translational Modifications\n\n- **N-linked glycosylation**: Multiple sites in granulin repeats\n- **Signal peptide cleavage**: Generates mature secreted protein\n- **Proteolytic processing**: Generates active granulin fragments\n\n---\n\n## Normal Physiological Function\n\n### Neuronal Survival and Development\n\nProgranulin supports neuronal health through multiple mechanisms[@eriksen2007]:\n\n**Neurotrophic Activity:**\n- Promotes neurite outgrowth and branching\n- Supports neuronal differentiation\n- Protects against excitotoxicity\n\n**Synaptic Function:**\n- Regulates synaptic plasticity\n- Modulates neurotransmitter release\n- Maintains dendritic spine morphology\n\n**Anti-apoptotic Effects:**\n- Protects neurons from various toxic insults\n- Reduces caspase activation\n- Supports mitochondrial function\n\n### Lysosomal Function\n\nA critical function of PGRN is its role in lysosomal homeostasis[@paushter2018]:\n\n**Lysosomal Enzyme Trafficking:**\n- Facilitates proper trafficking of cathepsin D\n- Regulates other lysosomal hydrolases\n- Maintains lysosomal pH\n\n**Autophagy Regulation:**\n- Modulates autophagic flux\n- Controls cargo delivery to lysosomes\n- Essential for autophagosome-lysosome fusion\n\n**Lipid Metabolism:**\n- Influences lysosomal lipid processing\n- Affects membrane composition\n- Critical for neuronal lipid homeostasis[@evers2023]\n\n### Immune Modulation\n\nPGRN exerts immunomodulatory effects throughout the body[@zhang2019]:\n\n**Inflammatory Response:**\n- Regulates cytokine production\n- Modulates immune cell activation\n- Can be pro- or anti-inflammatory depending on context\n\n**Microglial Function:**\n- Critical for microglial survival\n- Maintains microglial morphology\n- Regulates phagocytic activity\n\n**Wound Healing:**\n- Originally identified as a growth factor involved in tissue repair\n- Promotes angiogenesis\n- Supports tissue remodeling\n\n---\n\n## Pathogenic Mechanisms\n\n### Haploinsufficiency\n\nMost pathogenic [GRN](/genes/grn) mutations lead to reduced protein levels through haploinsufficiency:\n\n| Mutation Type | Mechanism |\n|--------------|------------|\n| Nonsense mutations | Premature stop codons causing nonsense-mediated decay |\n| Frameshift mutations | Insertions/deletions altering protein reading frame |\n| Splice site mutations | Aberrant mRNA processing |\n| Copy number deletions | Heterozygous deletions encompassing GRN |\n\nThe 50% reduction in PGRN levels is sufficient to cause FTD, demonstrating the critical importance of progranulin in neuronal maintenance.\n\n### Lysosomal Dysfunction\n\nLoss of functional PGRN leads to lysosomal impairment:\n\n1. **Cathepsin D deficiency**: Impaired processing of lysosomal substrates\n2. **Lipofuscin accumulation**: Accumulation of undigested material\n3. **Autophagic stress**: Impaired clearance of autophagic cargo\n4. **Lipid alterations**: Lysosomal lipid accumulation\n5. **Neuronal vulnerability**: Age-related neurodegeneration[@arrant2023]\n\n### TDP-43 Pathology\n\nPGRN deficiency leads to [TDP-43](/proteins/tdp-43) (encoded by [TARDBP](/genes/tardbp)) mislocalization:\n\n- **Nuclear clearance**: TDP-43 translocates from nucleus to cytoplasm\n- **Aggregation**: Cytoplasmic TDP-43 inclusions form\n- **Splicing dysregulation**: Loss of nuclear TDP-43 disrupts mRNA processing\n- **Neuronal loss**: TDP-43 pathology correlates with neurodegeneration\n\n### Neuroinflammation\n\nPGRN deficiency promotes neuroinflammation:\n- Increased microglial activation\n- Enhanced cytokine production\n- Altered immune responses\n\n---\n\n## Role in Neurodegenerative Diseases\n\n### Frontotemporal Dementia (FTD)\n\nGRN mutations cause TDP-43-positive FTD, representing one of the most common genetic forms:\n\n| FTD Subtype | Percentage of GRN Cases |\n|-------------|----------------------|\n| Behavioral variant FTD | ~60% |\n| Primary progressive aphasia | ~25% |\n| Corticobasal syndrome | ~15% |\n\n**Clinical Features:**\n- **Age of onset**: Typically 45-65 years\n- **Disease duration**: 5-12 years\n- **Behavioral changes**: Disinhibition, apathy, loss of empathy\n- **Language impairment**: Progressive aphasia variants\n- **Motor symptoms**: Corticobasal syndrome features\n\n**Pathology:**\n- TDP-43 inclusions in neurons and glia\n- Predominantly type B (cytoplasmic) pathology\n- Neuronal loss and gliosis\n\n### Amyotrophic Lateral Sclerosis (ALS)\n\nSome GRN mutations cause ALS or ALS/FTD:\n\n- Overlapping TDP-43 pathology with FTD\n- Combined upper and lower motor neuron signs\n- More rapid progression than FTD alone\n- May represent a disease continuum\n\n### Alzheimer's Disease\n\nGRN may modify AD risk[@chintapaludi2021]:\n- Some GRN variants associated with increased AD risk\n- PGRN levels altered in AD brains\n- Potential interactions with amyloid and [tau](/proteins/tau) pathology\n- May influence microglial responses in AD\n\n### Other Conditions\n\n- **Neuronal Ceroid Lipofuscinosis**: PGRN deficiency can cause similar pathology\n- **Age-related macular degeneration**: PGRN variants associated with risk\n\n---\n\n## Therapeutic Strategies\n\n### PGRN Replacement\n\nMultiple approaches to restore PGRN levels[@nguyen2021]:\n\n| Strategy | Approach | Status |\n|----------|----------|--------|\n| Recombinant PGRN | Systemically administered protein | Preclinical |\n| Gene therapy | AAV-mediated GRN delivery | Preclinical/early clinical |\n| Small molecule inducers | Increase GRN expression | Discovery |\n| Protein stabilization | Prevent PGRN degradation | Research |\n\n### Lysosomal Enhancement\n\nAddress lysosomal dysfunction in PGRN deficiency:\n\n1. **Cathepsin D activators**: Enhance lysosomal enzyme activity\n2. **Autophagy modulators**: [mTOR](/mechanisms/mtor-signaling-pathway) inhibitors, rapamycin analogs\n3. **Lipid metabolism modifiers**: Address lysosomal lipid accumulation\n4. **Gene therapy for lysosomal enzymes**: Restore enzymatic function\n\n### Anti-TDP-43 Approaches\n\nTarget downstream pathology:\n\n1. **ASO therapy**: Antisense oligonucleotides targeting TARDBP\n2. **Phosphorylation modulators**: Kinase inhibitors reducing TDP-43 pathology\n3. **Aggregation inhibitors**: Compounds preventing TDP-43 aggregation\n4. **Nuclear import enhancers**: Promote TDP-43 nuclear localization\n\n### Immunomodulation\n\n- Microglial modulators\n- Anti-inflammatory approaches\n- Cytokine-targeted therapies\n\n---\n\n## Biomarkers\n\n### Plasma/Serum PGRN\n\n- **Levels**: Reduced in GRN mutation carriers (heterozygotes ~50% of normal)\n- **Use**: Screening tool for genetic testing\n- **Advantage**: Non-invasive, widely available\n- **Limitations**: Not specific to FTD, overlap with other conditions[@meeter2016]\n\n### CSF Biomarkers\n\n| Marker | Changes in GRN-FTD |\n|--------|-------------------|\n| Total [tau](/proteins/tau) | Elevated |\n| Neurofilament light chain (NfL) | Markedly elevated |\n| Cathepsin D activity | Reduced |\n| PGRN | Reduced (~50%) |\n\n### Imaging\n\n- MRI for brain atrophy patterns\n- FDG-PET for hypometabolism\n- PET for neuroinflammation\n\n### Genetic Testing\n\n- Sequencing of GRN coding region\n- Deletion/duplication analysis\n- Family testing for at-risk individuals\n\n---\n\n## Animal Models\n\n### Grn Knockout Mice\n\n- **Phenotype**: Develop lipofuscin accumulation, microgliosis\n- **Behavior**: Show subtle cognitive deficits\n- **Aging**: Accelerate age-related neurodegeneration\n- **Therapeutic response**: PGRN administration improves phenotypes[@ahmed2010]\n\n### Drosophila Models\n\n- **PGRN homolog**: Drosophila contains a functional ortholog (Pgranulin)\n- **Loss-of-function**: Causes neurodegeneration\n- **Genetic modifiers**: Identifies relevant pathways\n\n### Non-Human Primates\n\n- Limited studies in non-human primates\n- Important for translational studies\n\n---\n\n## Cross-References\n\n- [GRN Gene](/genes/grn)\n- [TDP-43 Protein](/proteins/tdp-43)\n- [Frontotemporal Dementia](/diseases/frontotemporal-dementia)\n- [Amyotrophic Lateral Sclerosis](/diseases/als)\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Lysosomal Dysfunction](/mechanisms/lysosomal-dysfunction)\n- [Autophagy](/mechanisms/autophagy)\n- [Neuroinflammation](/mechanisms/neuroinflammation)\n\n---\n\n## Key Publications\n\n1. [Baker M, et al. Mutations in progranulin cause tau-negative frontotemporal dementia. Nature. 2006.](https://pubmed.ncbi.nlm.nih.gov/16625161/)\n2. [Eriksen JL, Mackenzie IR. Progranulin: a new player in neurobiology. J Neurochem. 2007.](https://pubmed.ncbi.nlm.nih.gov/17727630/)\n3. [Chintapaludi M, Baloh RH. Progranulin in the pathogenesis of AD and related dementias. Neurobiol Aging. 2021.](https://pubmed.ncbi.nlm.nih.gov/33865236/)\n4. [Götzl JK, et al. Understanding GRN-linked FTD. Trends Neurosci. 2020.](https://pubmed.ncbi.nlm.nih.gov/32291132/)\n5. [Minami SS, et al. Progranulin deficiency promotes neuroinflammation. J Clin Invest. 2020.](https://pubmed.ncbi.nlm.nih.gov/32271718/)\n6. [Paushter DH, et al. The lysosomal function of progranulin. Immunobiology. 2018.](https://pubmed.ncbi.nlm.nih.gov/30268483/)\n7. [Zhang Y, et al. Progranulin: a key player in microglial function. Nat Rev Neurol. 2019.](https://pubmed.ncbi.nlm.nih.gov/31073201/)\n8. [Arrant AE, Roberson ED. Therapeutic strategies for progranulin-deficient FTD. Neuron. 2023.](https://pubmed.ncbi.nlm.nih.gov/36917592/)\n9. [Nguyen AD, et al. A progranulin-derived therapeutic antibody restores synaptic function. Sci Transl Med. 2021.](https://pubmed.ncbi.nlm.nih.gov/33568476/)\n10. [Evers BM, et al. Lipid alterations and lysosomal dysfunction in progranulin-deficient neurons. Nat Commun. 2023.](https://pubmed.ncbi.nlm.nih.gov/37019960/)\n\n---\n\n## External Links\n\n- **UniProt**: [P28799](https://www.uniprot.org/uniprot/P28799)\n- **AlphaFold**: [PGRN](https://alphafold.ebi.ac.uk/entry/P28799)\n- **PDB**: [2JYE](https://www.rcsb.org/structure/2JYE)\n- **NCBI Gene**: [GRN](https://www.ncbi.nlm.nih.gov/gene/5136)\n- **OMIM**: [607486](https://www.omim.org/entry/607486)\n- **GeneCards**: [GRN](https://www.genecards.org/cgi-bin/carddisp.pl?gene=GRN)\n\n---\n\n## References\n\n[@baker2006]: Baker M, et al. [Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17](https://pubmed.ncbi.nlm.nih.gov/16625161/). *Nature*. 2006.\n\n[@eriksen2007]: Eriksen JL, Mackenzie IR. [Progranulin: a new player in neurobiology](https://pubmed.ncbi.nlm.nih.gov/17727630/). *J Neurochem*. 2007.\n\n[@chintapaludi2021]: Chintapaludi M, Baloh RH. [Progranulin in the pathogenesis of Alzheimer's disease and related dementias](https://pubmed.ncbi.nlm.nih.gov/33865236/). *Neurobiol Aging*. 2021.\n\n[@gtzl2020]: Götzl JK, Capell A, Haass C. [Understanding GRN-linked FTD](https://pubmed.ncbi.nlm.nih.gov/32291132/). *Trends Neurosci*. 2020.\n\n[@minami2020]: Minami SS, et al. [Progranulin deficiency promotes neuroinflammation and selectively increases adult hippocampal neurogenesis](https://pubmed.ncbi.nlm.nih.gov/32271718/). *J Clin Invest*. 2020.\n\n[@paushter2018]: Paushter DH, et al. [The lysosomal function of progranulin](https://pubmed.ncbi.nlm.nih.gov/30268483/). *Immunobiology*. 2018.\n\n[@zhang2019]: Zhang Y, Chen X, Zong J. [Progranulin: a key player in microglial function](https://pubmed.ncbi.nlm.nih.gov/31073201/). *Nat Rev Neurol*. 2019.\n\n[@irwin2019]: Irwin DJ, et al. [Frontotemporal lobar degeneration: TDP-43 pathology and the role of GRN mutations](https://pubmed.ncbi.nlm.nih.gov/30848362/). *Acta Neuropathol*. 2019.\n\n[@arrant2023]: Arrant AE, Roberson ED. [Therapeutic strategies for progranulin-deficient FTD](https://pubmed.ncbi.nlm.nih.gov/36917592/). *Neuron*. 2023.\n\n[@nguyen2021]: Nguyen AD, et al. [A progranulin-derived therapeutic antibody restores synaptic function](https://pubmed.ncbi.nlm.nih.gov/33568476/). *Sci Transl Med*. 2021.\n\n[@evers2023]: Evers BM, et al. [Lipid alterations and lysosomal dysfunction in progranulin-deficient neurons](https://pubmed.ncbi.nlm.nih.gov/37019960/). *Nat Commun*. 2023.\n\n[@meeter2016]: Meeter LH, et al. [Plasma and CSF progranulin in genetic FTD](https://pubmed.ncbi.nlm.nih.gov/26718579/). *Neurology*. 2016.\n\n[@ahmed2010]: Ahmed Z, et al. [Accelerated lipofuscino genesis and microglial activation in progranulin-deficient mice](https://pubmed.ncbi.nlm.nih.gov/19501490/). *Neurobiol Aging*. 2010.",
  "entity_type": "protein"
}

{
  "content_md": "# Progranulin Protein (PGRN)\n\n<table class=\"infobox infobox-protein\">\n  <tr>\n    <th class=\"infobox-header\" colspan=\"2\">Progranulin (PGRN)</th>\n  </tr>\n  <tr>\n    <td class=\"label\">Gene</td>\n    <td>[GRN](/genes/grn)</td>\n  </tr>\n  <tr>\n    <td class=\"label\">UniProt</td>\n    <td><a href=\"https://www.uniprot.org/uniprot/P28799\" target=\"_blank\">P28799</a></td>\n  </tr>\n  <tr>\n    <td class=\"label\">Protein Name</td>\n    <td>Progranulin</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Molecular Weight</td>\n    <td>63.5 kDa (full-length); secreted fragments: 6-25 kDa</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Length</td>\n    <td>593 amino acids</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Localization</td>\n    <td>Secreted, Lysosomes, Cytoplasm</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Expression</td>\n    <td>Neurons, Microglia, Macrophages, Epithelial cells</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Associated Diseases</td>\n    <td>[Frontotemporal Dementia](/diseases/frontotemporal-dementia), [Amyotrophic Lateral Sclerosis](/diseases/als), [Alzheimer's Disease](/diseases/alzheimers-disease)</td>\n  </tr>\n</table>\n\n# Progranulin Protein (PGRN)\n\n## Overview\n\n**Progranulin (PGRN)** is a secreted glycoprotein encoded by the [GRN](/genes/grn) gene that functions as a crucial regulator of neuronal survival, lysosomal function, immune response, and synaptic plasticity. The protein has a molecular weight of 63.5 kDa in its full-length form and is proteolytically processed into smaller granulins (6-25 kDa) that have distinct biological activities[@baker2006]. Progranulin is localized to multiple cellular compartments including the secretory pathway, lysosomes, and cytoplasm, where it participates in diverse cellular processes[@chintapaludi2021].\n\nHaploinsufficiency caused by [GRN](/genes/grn) mutations is one of the most common genetic causes of [frontotemporal dementia (FTD)](/diseases/frontotemporal-dementia), accounting for approximately 5-10% of all FTD cases and up to 20% of familial FTD[@gtzl2020]. Additionally, GRN mutations have been implicated in [amyotrophic lateral sclerosis (ALS)](/diseases/als) and may modify [Alzheimer's disease (AD)](/diseases/alzheimers-disease) risk. The discovery that GRN mutations cause FTD through a haploinsufficiency mechanism, resulting in approximately 50% reduction in functional protein levels, has driven significant therapeutic development efforts focused on protein replacement or upregulation[@arrant2023].\n\n---\n\n## Structure and Biochemistry\n\n### Primary Structure\n\nProgranulin is a 593-amino acid secreted glycoprotein with a molecular weight of 63.5 kDa. The protein contains multiple functional domains:\n\n| Domain | Position | Description |\n|--------|----------|-------------|\n| Signal peptide | 1-18 | Directs secretion via secretory pathway |\n| Granulin repeats | 19-564 | 7.5 tandem repeats of ~60-80 aa each |\n| Cysteine-rich regions | Between repeats | Provide structural stability |\n| N-glycosylation sites | Multiple | Affect secretion and stability |\n\n### Granulin Repeats\n\nThe hallmark of progranulin is its series of granulin repeats:\n- **P-granulin (full-length)**: Contains all 7.5 repeats\n- **Granulin A-G**: Individual repeats released by proteolytic cleavage\n- **Paragranulin**: Contains only the first four repeats\n\nEach granulin repeat contains:\n- 12 conserved cysteine residues forming disulfide bonds\n- Characteristic \"Gliadin\" fold\n- Protease resistance due to dense disulfide bonding\n\n### Proteolytic Processing\n\nProgranulin is cleaved by multiple proteases:\n\n| Protease | Cleavage Site | Result |\n|----------|---------------|--------|\n| Elastase | Between repeats | Granulin fragments |\n| Matrix metalloproteinases (MMP-3, MMP-9) | Variable | Multiple fragments |\n| Cathepsin D | Within repeats | Smaller fragments |\n| ADAMTS-4 | N-terminal | Truncated forms |\n\nThe cleavage products (granulins) have distinct biological activities:\n- Some granulins are neurotrophic\n- Others may have inflammatory functions\n- Balance between full-length PGRN and fragments is biologically important\n\n### Post-Translational Modifications\n\n- **N-linked glycosylation**: Multiple sites in granulin repeats\n- **Signal peptide cleavage**: Generates mature secreted protein\n- **Proteolytic processing**: Generates active granulin fragments\n\n---\n\n## Normal Physiological Function\n\n### Neuronal Survival and Development\n\nProgranulin supports neuronal health through multiple mechanisms[@eriksen2007]:\n\n**Neurotrophic Activity:**\n- Promotes neurite outgrowth and branching\n- Supports neuronal differentiation\n- Protects against excitotoxicity\n\n**Synaptic Function:**\n- Regulates synaptic plasticity\n- Modulates neurotransmitter release\n- Maintains dendritic spine morphology\n\n**Anti-apoptotic Effects:**\n- Protects neurons from various toxic insults\n- Reduces caspase activation\n- Supports mitochondrial function\n\n### Lysosomal Function\n\nA critical function of PGRN is its role in lysosomal homeostasis[@paushter2018]:\n\n**Lysosomal Enzyme Trafficking:**\n- Facilitates proper trafficking of cathepsin D\n- Regulates other lysosomal hydrolases\n- Maintains lysosomal pH\n\n**Autophagy Regulation:**\n- Modulates autophagic flux\n- Controls cargo delivery to lysosomes\n- Essential for autophagosome-lysosome fusion\n\n**Lipid Metabolism:**\n- Influences lysosomal lipid processing\n- Affects membrane composition\n- Critical for neuronal lipid homeostasis[@evers2023]\n\n### Immune Modulation\n\nPGRN exerts immunomodulatory effects throughout the body[@zhang2019]:\n\n**Inflammatory Response:**\n- Regulates cytokine production\n- Modulates immune cell activation\n- Can be pro- or anti-inflammatory depending on context\n\n**Microglial Function:**\n- Critical for microglial survival\n- Maintains microglial morphology\n- Regulates phagocytic activity\n\n**Wound Healing:**\n- Originally identified as a growth factor involved in tissue repair\n- Promotes angiogenesis\n- Supports tissue remodeling\n\n---\n\n## Pathogenic Mechanisms\n\n### Haploinsufficiency\n\nMost pathogenic [GRN](/genes/grn) mutations lead to reduced protein levels through haploinsufficiency:\n\n| Mutation Type | Mechanism |\n|--------------|------------|\n| Nonsense mutations | Premature stop codons causing nonsense-mediated decay |\n| Frameshift mutations | Insertions/deletions altering protein reading frame |\n| Splice site mutations | Aberrant mRNA processing |\n| Copy number deletions | Heterozygous deletions encompassing GRN |\n\nThe 50% reduction in PGRN levels is sufficient to cause FTD, demonstrating the critical importance of progranulin in neuronal maintenance.\n\n### Lysosomal Dysfunction\n\nLoss of functional PGRN leads to lysosomal impairment:\n\n1. **Cathepsin D deficiency**: Impaired processing of lysosomal substrates\n2. **Lipofuscin accumulation**: Accumulation of undigested material\n3. **Autophagic stress**: Impaired clearance of autophagic cargo\n4. **Lipid alterations**: Lysosomal lipid accumulation\n5. **Neuronal vulnerability**: Age-related neurodegeneration[@arrant2023]\n\n### TDP-43 Pathology\n\nPGRN deficiency leads to [TDP-43](/proteins/tdp-43) (encoded by [TARDBP](/genes/tardbp)) mislocalization:\n\n- **Nuclear clearance**: TDP-43 translocates from nucleus to cytoplasm\n- **Aggregation**: Cytoplasmic TDP-43 inclusions form\n- **Splicing dysregulation**: Loss of nuclear TDP-43 disrupts mRNA processing\n- **Neuronal loss**: TDP-43 pathology correlates with neurodegeneration\n\n### Neuroinflammation\n\nPGRN deficiency promotes neuroinflammation:\n- Increased microglial activation\n- Enhanced cytokine production\n- Altered immune responses\n\n---\n\n## Role in Neurodegenerative Diseases\n\n### Frontotemporal Dementia (FTD)\n\nGRN mutations cause TDP-43-positive FTD, representing one of the most common genetic forms:\n\n| FTD Subtype | Percentage of GRN Cases |\n|-------------|----------------------|\n| Behavioral variant FTD | ~60% |\n| Primary progressive aphasia | ~25% |\n| Corticobasal syndrome | ~15% |\n\n**Clinical Features:**\n- **Age of onset**: Typically 45-65 years\n- **Disease duration**: 5-12 years\n- **Behavioral changes**: Disinhibition, apathy, loss of empathy\n- **Language impairment**: Progressive aphasia variants\n- **Motor symptoms**: Corticobasal syndrome features\n\n**Pathology:**\n- TDP-43 inclusions in neurons and glia\n- Predominantly type B (cytoplasmic) pathology\n- Neuronal loss and gliosis\n\n### Amyotrophic Lateral Sclerosis (ALS)\n\nSome GRN mutations cause ALS or ALS/FTD:\n\n- Overlapping TDP-43 pathology with FTD\n- Combined upper and lower motor neuron signs\n- More rapid progression than FTD alone\n- May represent a disease continuum\n\n### Alzheimer's Disease\n\nGRN may modify AD risk[@chintapaludi2021]:\n- Some GRN variants associated with increased AD risk\n- PGRN levels altered in AD brains\n- Potential interactions with amyloid and [tau](/proteins/tau) pathology\n- May influence microglial responses in AD\n\n### Other Conditions\n\n- **Neuronal Ceroid Lipofuscinosis**: PGRN deficiency can cause similar pathology\n- **Age-related macular degeneration**: PGRN variants associated with risk\n\n---\n\n## Therapeutic Strategies\n\n### PGRN Replacement\n\nMultiple approaches to restore PGRN levels[@nguyen2021]:\n\n| Strategy | Approach | Status |\n|----------|----------|--------|\n| Recombinant PGRN | Systemically administered protein | Preclinical |\n| Gene therapy | AAV-mediated GRN delivery | Preclinical/early clinical |\n| Small molecule inducers | Increase GRN expression | Discovery |\n| Protein stabilization | Prevent PGRN degradation | Research |\n\n### Lysosomal Enhancement\n\nAddress lysosomal dysfunction in PGRN deficiency:\n\n1. **Cathepsin D activators**: Enhance lysosomal enzyme activity\n2. **Autophagy modulators**: [mTOR](/mechanisms/mtor-signaling-pathway) inhibitors, rapamycin analogs\n3. **Lipid metabolism modifiers**: Address lysosomal lipid accumulation\n4. **Gene therapy for lysosomal enzymes**: Restore enzymatic function\n\n### Anti-TDP-43 Approaches\n\nTarget downstream pathology:\n\n1. **ASO therapy**: Antisense oligonucleotides targeting TARDBP\n2. **Phosphorylation modulators**: Kinase inhibitors reducing TDP-43 pathology\n3. **Aggregation inhibitors**: Compounds preventing TDP-43 aggregation\n4. **Nuclear import enhancers**: Promote TDP-43 nuclear localization\n\n### Immunomodulation\n\n- Microglial modulators\n- Anti-inflammatory approaches\n- Cytokine-targeted therapies\n\n---\n\n## Biomarkers\n\n### Plasma/Serum PGRN\n\n- **Levels**: Reduced in GRN mutation carriers (heterozygotes ~50% of normal)\n- **Use**: Screening tool for genetic testing\n- **Advantage**: Non-invasive, widely available\n- **Limitations**: Not specific to FTD, overlap with other conditions[@meeter2016]\n\n### CSF Biomarkers\n\n| Marker | Changes in GRN-FTD |\n|--------|-------------------|\n| Total [tau](/proteins/tau) | Elevated |\n| Neurofilament light chain (NfL) | Markedly elevated |\n| Cathepsin D activity | Reduced |\n| PGRN | Reduced (~50%) |\n\n### Imaging\n\n- MRI for brain atrophy patterns\n- FDG-PET for hypometabolism\n- PET for neuroinflammation\n\n### Genetic Testing\n\n- Sequencing of GRN coding region\n- Deletion/duplication analysis\n- Family testing for at-risk individuals\n\n---\n\n## Animal Models\n\n### Grn Knockout Mice\n\n- **Phenotype**: Develop lipofuscin accumulation, microgliosis\n- **Behavior**: Show subtle cognitive deficits\n- **Aging**: Accelerate age-related neurodegeneration\n- **Therapeutic response**: PGRN administration improves phenotypes[@ahmed2010]\n\n### Drosophila Models\n\n- **PGRN homolog**: Drosophila contains a functional ortholog (Pgranulin)\n- **Loss-of-function**: Causes neurodegeneration\n- **Genetic modifiers**: Identifies relevant pathways\n\n### Non-Human Primates\n\n- Limited studies in non-human primates\n- Important for translational studies\n\n---\n\n## Cross-References\n\n- [GRN Gene](/genes/grn)\n- [TDP-43 Protein](/proteins/tdp-43)\n- [Frontotemporal Dementia](/diseases/frontotemporal-dementia)\n- [Amyotrophic Lateral Sclerosis](/diseases/als)\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Lysosomal Dysfunction](/mechanisms/lysosomal-dysfunction)\n- [Autophagy](/mechanisms/autophagy)\n- [Neuroinflammation](/mechanisms/neuroinflammation)\n\n---\n\n## Key Publications\n\n1. [Baker M, et al. Mutations in progranulin cause tau-negative frontotemporal dementia. Nature. 2006.](https://pubmed.ncbi.nlm.nih.gov/16625161/)\n2. [Eriksen JL, Mackenzie IR. Progranulin: a new player in neurobiology. J Neurochem. 2007.](https://pubmed.ncbi.nlm.nih.gov/17727630/)\n3. [Chintapaludi M, Baloh RH. Progranulin in the pathogenesis of AD and related dementias. Neurobiol Aging. 2021.](https://pubmed.ncbi.nlm.nih.gov/33865236/)\n4. [Götzl JK, et al. Understanding GRN-linked FTD. Trends Neurosci. 2020.](https://pubmed.ncbi.nlm.nih.gov/32291132/)\n5. [Minami SS, et al. Progranulin deficiency promotes neuroinflammation. J Clin Invest. 2020.](https://pubmed.ncbi.nlm.nih.gov/32271718/)\n6. [Paushter DH, et al. The lysosomal function of progranulin. Immunobiology. 2018.](https://pubmed.ncbi.nlm.nih.gov/30268483/)\n7. [Zhang Y, et al. Progranulin: a key player in microglial function. Nat Rev Neurol. 2019.](https://pubmed.ncbi.nlm.nih.gov/31073201/)\n8. [Arrant AE, Roberson ED. Therapeutic strategies for progranulin-deficient FTD. Neuron. 2023.](https://pubmed.ncbi.nlm.nih.gov/36917592/)\n9. [Nguyen AD, et al. A progranulin-derived therapeutic antibody restores synaptic function. Sci Transl Med. 2021.](https://pubmed.ncbi.nlm.nih.gov/33568476/)\n10. [Evers BM, et al. Lipid alterations and lysosomal dysfunction in progranulin-deficient neurons. Nat Commun. 2023.](https://pubmed.ncbi.nlm.nih.gov/37019960/)\n\n---\n\n## External Links\n\n- **UniProt**: [P28799](https://www.uniprot.org/uniprot/P28799)\n- **AlphaFold**: [PGRN](https://alphafold.ebi.ac.uk/entry/P28799)\n- **PDB**: [2JYE](https://www.rcsb.org/structure/2JYE)\n- **NCBI Gene**: [GRN](https://www.ncbi.nlm.nih.gov/gene/5136)\n- **OMIM**: [607486](https://www.omim.org/entry/607486)\n- **GeneCards**: [GRN](https://www.genecards.org/cgi-bin/carddisp.pl?gene=GRN)\n\n---\n\n## References\n\n[@baker2006]: Baker M, et al. [Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17](https://pubmed.ncbi.nlm.nih.gov/16625161/). *Nature*. 2006.\n\n[@eriksen2007]: Eriksen JL, Mackenzie IR. [Progranulin: a new player in neurobiology](https://pubmed.ncbi.nlm.nih.gov/17727630/). *J Neurochem*. 2007.\n\n[@chintapaludi2021]: Chintapaludi M, Baloh RH. [Progranulin in the pathogenesis of Alzheimer's disease and related dementias](https://pubmed.ncbi.nlm.nih.gov/33865236/). *Neurobiol Aging*. 2021.\n\n[@gtzl2020]: Götzl JK, Capell A, Haass C. [Understanding GRN-linked FTD](https://pubmed.ncbi.nlm.nih.gov/32291132/). *Trends Neurosci*. 2020.\n\n[@minami2020]: Minami SS, et al. [Progranulin deficiency promotes neuroinflammation and selectively increases adult hippocampal neurogenesis](https://pubmed.ncbi.nlm.nih.gov/32271718/). *J Clin Invest*. 2020.\n\n[@paushter2018]: Paushter DH, et al. [The lysosomal function of progranulin](https://pubmed.ncbi.nlm.nih.gov/30268483/). *Immunobiology*. 2018.\n\n[@zhang2019]: Zhang Y, Chen X, Zong J. [Progranulin: a key player in microglial function](https://pubmed.ncbi.nlm.nih.gov/31073201/). *Nat Rev Neurol*. 2019.\n\n[@irwin2019]: Irwin DJ, et al. [Frontotemporal lobar degeneration: TDP-43 pathology and the role of GRN mutations](https://pubmed.ncbi.nlm.nih.gov/30848362/). *Acta Neuropathol*. 2019.\n\n[@arrant2023]: Arrant AE, Roberson ED. [Therapeutic strategies for progranulin-deficient FTD](https://pubmed.ncbi.nlm.nih.gov/36917592/). *Neuron*. 2023.\n\n[@nguyen2021]: Nguyen AD, et al. [A progranulin-derived therapeutic antibody restores synaptic function](https://pubmed.ncbi.nlm.nih.gov/33568476/). *Sci Transl Med*. 2021.\n\n[@evers2023]: Evers BM, et al. [Lipid alterations and lysosomal dysfunction in progranulin-deficient neurons](https://pubmed.ncbi.nlm.nih.gov/37019960/). *Nat Commun*. 2023.\n\n[@meeter2016]: Meeter LH, et al. [Plasma and CSF progranulin in genetic FTD](https://pubmed.ncbi.nlm.nih.gov/26718579/). *Neurology*. 2016.\n\n[@ahmed2010]: Ahmed Z, et al. [Accelerated lipofuscino genesis and microglial activation in progranulin-deficient mice](https://pubmed.ncbi.nlm.nih.gov/19501490/). *Neurobiol Aging*. 2010.",
  "entity_type": "protein"
}

{
  "content_md": "<table class=\"infobox infobox-protein\">\n  <tr>\n    <th class=\"infobox-header\" colspan=\"2\">Progranulin (PGRN)</th>\n  </tr>\n  <tr>\n    <td class=\"label\">Gene</td>\n    <td>[GRN](/genes/grn)</td>\n  </tr>\n  <tr>\n    <td class=\"label\">UniProt</td>\n    <td><a href=\"https://www.uniprot.org/uniprot/P28799\" target=\"_blank\">P28799</a></td>\n  </tr>\n  <tr>\n    <td class=\"label\">Protein Name</td>\n    <td>Progranulin</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Molecular Weight</td>\n    <td>63.5 kDa (full-length); secreted fragments: 6-25 kDa</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Length</td>\n    <td>593 amino acids</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Localization</td>\n    <td>Secreted, Lysosomes, Cytoplasm</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Expression</td>\n    <td>Neurons, Microglia, Macrophages, Epithelial cells</td>\n  </tr>\n  <tr>\n    <td class=\"label\">Associated Diseases</td>\n    <td>[Frontotemporal Dementia](/diseases/frontotemporal-dementia), [Amyotrophic Lateral Sclerosis](/diseases/als), [Alzheimer's Disease](/diseases/alzheimers-disease)</td>\n  </tr>\n</table>\n\n# Progranulin Protein (PGRN)\n\n## Overview\n\n**Progranulin (PGRN)** is a secreted glycoprotein encoded by the [GRN](/genes/grn) gene that functions as a crucial regulator of neuronal survival, lysosomal function, immune response, and synaptic plasticity. The protein has a molecular weight of 63.5 kDa in its full-length form and is proteolytically processed into smaller granulins (6-25 kDa) that have distinct biological activities[@baker2006]. Progranulin is localized to multiple cellular compartments including the secretory pathway, lysosomes, and cytoplasm, where it participates in diverse cellular processes[@chintapaludi2021].\n\nHaploinsufficiency caused by [GRN](/genes/grn) mutations is one of the most common genetic causes of [frontotemporal dementia (FTD)](/diseases/frontotemporal-dementia), accounting for approximately 5-10% of all FTD cases and up to 20% of familial FTD[@gtzl2020]. Additionally, GRN mutations have been implicated in [amyotrophic lateral sclerosis (ALS)](/diseases/als) and may modify [Alzheimer's disease (AD)](/diseases/alzheimers-disease) risk. The discovery that GRN mutations cause FTD through a haploinsufficiency mechanism, resulting in approximately 50% reduction in functional protein levels, has driven significant therapeutic development efforts focused on protein replacement or upregulation[@arrant2023].\n\n---\n\n## Structure and Biochemistry\n\n### Primary Structure\n\nProgranulin is a 593-amino acid secreted glycoprotein with a molecular weight of 63.5 kDa. The protein contains multiple functional domains:\n\n| Domain | Position | Description |\n|--------|----------|-------------|\n| Signal peptide | 1-18 | Directs secretion via secretory pathway |\n| Granulin repeats | 19-564 | 7.5 tandem repeats of ~60-80 aa each |\n| Cysteine-rich regions | Between repeats | Provide structural stability |\n| N-glycosylation sites | Multiple | Affect secretion and stability |\n\n### Granulin Repeats\n\nThe hallmark of progranulin is its series of granulin repeats:\n- **P-granulin (full-length)**: Contains all 7.5 repeats\n- **Granulin A-G**: Individual repeats released by proteolytic cleavage\n- **Paragranulin**: Contains only the first four repeats\n\nEach granulin repeat contains:\n- 12 conserved cysteine residues forming disulfide bonds\n- Characteristic \"Gliadin\" fold\n- Protease resistance due to dense disulfide bonding\n\n### Proteolytic Processing\n\nProgranulin is cleaved by multiple proteases:\n\n| Protease | Cleavage Site | Result |\n|----------|---------------|--------|\n| Elastase | Between repeats | Granulin fragments |\n| Matrix metalloproteinases (MMP-3, MMP-9) | Variable | Multiple fragments |\n| Cathepsin D | Within repeats | Smaller fragments |\n| ADAMTS-4 | N-terminal | Truncated forms |\n\nThe cleavage products (granulins) have distinct biological activities:\n- Some granulins are neurotrophic\n- Others may have inflammatory functions\n- Balance between full-length PGRN and fragments is biologically important\n\n### Post-Translational Modifications\n\n- **N-linked glycosylation**: Multiple sites in granulin repeats\n- **Signal peptide cleavage**: Generates mature secreted protein\n- **Proteolytic processing**: Generates active granulin fragments\n\n---\n\n## Normal Physiological Function\n\n### Neuronal Survival and Development\n\nProgranulin supports neuronal health through multiple mechanisms[@eriksen2007]:\n\n**Neurotrophic Activity:**\n- Promotes neurite outgrowth and branching\n- Supports neuronal differentiation\n- Protects against excitotoxicity\n\n**Synaptic Function:**\n- Regulates synaptic plasticity\n- Modulates neurotransmitter release\n- Maintains dendritic spine morphology\n\n**Anti-apoptotic Effects:**\n- Protects neurons from various toxic insults\n- Reduces caspase activation\n- Supports mitochondrial function\n\n### Lysosomal Function\n\nA critical function of PGRN is its role in lysosomal homeostasis[@paushter2018]:\n\n**Lysosomal Enzyme Trafficking:**\n- Facilitates proper trafficking of cathepsin D\n- Regulates other lysosomal hydrolases\n- Maintains lysosomal pH\n\n**Autophagy Regulation:**\n- Modulates autophagic flux\n- Controls cargo delivery to lysosomes\n- Essential for autophagosome-lysosome fusion\n\n**Lipid Metabolism:**\n- Influences lysosomal lipid processing\n- Affects membrane composition\n- Critical for neuronal lipid homeostasis[@evers2023]\n\n### Immune Modulation\n\nPGRN exerts immunomodulatory effects throughout the body[@zhang2019]:\n\n**Inflammatory Response:**\n- Regulates cytokine production\n- Modulates immune cell activation\n- Can be pro- or anti-inflammatory depending on context\n\n**Microglial Function:**\n- Critical for microglial survival\n- Maintains microglial morphology\n- Regulates phagocytic activity\n\n**Wound Healing:**\n- Originally identified as a growth factor involved in tissue repair\n- Promotes angiogenesis\n- Supports tissue remodeling\n\n---\n\n## Pathogenic Mechanisms\n\n### Haploinsufficiency\n\nMost pathogenic [GRN](/genes/grn) mutations lead to reduced protein levels through haploinsufficiency:\n\n| Mutation Type | Mechanism |\n|--------------|------------|\n| Nonsense mutations | Premature stop codons causing nonsense-mediated decay |\n| Frameshift mutations | Insertions/deletions altering protein reading frame |\n| Splice site mutations | Aberrant mRNA processing |\n| Copy number deletions | Heterozygous deletions encompassing GRN |\n\nThe 50% reduction in PGRN levels is sufficient to cause FTD, demonstrating the critical importance of progranulin in neuronal maintenance.\n\n### Lysosomal Dysfunction\n\nLoss of functional PGRN leads to lysosomal impairment:\n\n1. **Cathepsin D deficiency**: Impaired processing of lysosomal substrates\n2. **Lipofuscin accumulation**: Accumulation of undigested material\n3. **Autophagic stress**: Impaired clearance of autophagic cargo\n4. **Lipid alterations**: Lysosomal lipid accumulation\n5. **Neuronal vulnerability**: Age-related neurodegeneration[@arrant2023]\n\n### TDP-43 Pathology\n\nPGRN deficiency leads to [TDP-43](/proteins/tdp-43) (encoded by [TARDBP](/genes/tardbp)) mislocalization:\n\n- **Nuclear clearance**: TDP-43 translocates from nucleus to cytoplasm\n- **Aggregation**: Cytoplasmic TDP-43 inclusions form\n- **Splicing dysregulation**: Loss of nuclear TDP-43 disrupts mRNA processing\n- **Neuronal loss**: TDP-43 pathology correlates with neurodegeneration\n\n### Neuroinflammation\n\nPGRN deficiency promotes neuroinflammation:\n- Increased microglial activation\n- Enhanced cytokine production\n- Altered immune responses\n\n---\n\n## Role in Neurodegenerative Diseases\n\n### Frontotemporal Dementia (FTD)\n\nGRN mutations cause TDP-43-positive FTD, representing one of the most common genetic forms:\n\n| FTD Subtype | Percentage of GRN Cases |\n|-------------|----------------------|\n| Behavioral variant FTD | ~60% |\n| Primary progressive aphasia | ~25% |\n| Corticobasal syndrome | ~15% |\n\n**Clinical Features:**\n- **Age of onset**: Typically 45-65 years\n- **Disease duration**: 5-12 years\n- **Behavioral changes**: Disinhibition, apathy, loss of empathy\n- **Language impairment**: Progressive aphasia variants\n- **Motor symptoms**: Corticobasal syndrome features\n\n**Pathology:**\n- TDP-43 inclusions in neurons and glia\n- Predominantly type B (cytoplasmic) pathology\n- Neuronal loss and gliosis\n\n### Amyotrophic Lateral Sclerosis (ALS)\n\nSome GRN mutations cause ALS or ALS/FTD:\n\n- Overlapping TDP-43 pathology with FTD\n- Combined upper and lower motor neuron signs\n- More rapid progression than FTD alone\n- May represent a disease continuum\n\n### Alzheimer's Disease\n\nGRN may modify AD risk[@chintapaludi2021]:\n- Some GRN variants associated with increased AD risk\n- PGRN levels altered in AD brains\n- Potential interactions with amyloid and [tau](/proteins/tau) pathology\n- May influence microglial responses in AD\n\n### Other Conditions\n\n- **Neuronal Ceroid Lipofuscinosis**: PGRN deficiency can cause similar pathology\n- **Age-related macular degeneration**: PGRN variants associated with risk\n\n---\n\n## Therapeutic Strategies\n\n### PGRN Replacement\n\nMultiple approaches to restore PGRN levels[@nguyen2021]:\n\n| Strategy | Approach | Status |\n|----------|----------|--------|\n| Recombinant PGRN | Systemically administered protein | Preclinical |\n| Gene therapy | AAV-mediated GRN delivery | Preclinical/early clinical |\n| Small molecule inducers | Increase GRN expression | Discovery |\n| Protein stabilization | Prevent PGRN degradation | Research |\n\n### Lysosomal Enhancement\n\nAddress lysosomal dysfunction in PGRN deficiency:\n\n1. **Cathepsin D activators**: Enhance lysosomal enzyme activity\n2. **Autophagy modulators**: [mTOR](/mechanisms/mtor-signaling-pathway) inhibitors, rapamycin analogs\n3. **Lipid metabolism modifiers**: Address lysosomal lipid accumulation\n4. **Gene therapy for lysosomal enzymes**: Restore enzymatic function\n\n### Anti-TDP-43 Approaches\n\nTarget downstream pathology:\n\n1. **ASO therapy**: Antisense oligonucleotides targeting TARDBP\n2. **Phosphorylation modulators**: Kinase inhibitors reducing TDP-43 pathology\n3. **Aggregation inhibitors**: Compounds preventing TDP-43 aggregation\n4. **Nuclear import enhancers**: Promote TDP-43 nuclear localization\n\n### Immunomodulation\n\n- Microglial modulators\n- Anti-inflammatory approaches\n- Cytokine-targeted therapies\n\n---\n\n## Biomarkers\n\n### Plasma/Serum PGRN\n\n- **Levels**: Reduced in GRN mutation carriers (heterozygotes ~50% of normal)\n- **Use**: Screening tool for genetic testing\n- **Advantage**: Non-invasive, widely available\n- **Limitations**: Not specific to FTD, overlap with other conditions[@meeter2016]\n\n### CSF Biomarkers\n\n| Marker | Changes in GRN-FTD |\n|--------|-------------------|\n| Total [tau](/proteins/tau) | Elevated |\n| Neurofilament light chain (NfL) | Markedly elevated |\n| Cathepsin D activity | Reduced |\n| PGRN | Reduced (~50%) |\n\n### Imaging\n\n- MRI for brain atrophy patterns\n- FDG-PET for hypometabolism\n- PET for neuroinflammation\n\n### Genetic Testing\n\n- Sequencing of GRN coding region\n- Deletion/duplication analysis\n- Family testing for at-risk individuals\n\n---\n\n## Animal Models\n\n### Grn Knockout Mice\n\n- **Phenotype**: Develop lipofuscin accumulation, microgliosis\n- **Behavior**: Show subtle cognitive deficits\n- **Aging**: Accelerate age-related neurodegeneration\n- **Therapeutic response**: PGRN administration improves phenotypes[@ahmed2010]\n\n### Drosophila Models\n\n- **PGRN homolog**: Drosophila contains a functional ortholog (Pgranulin)\n- **Loss-of-function**: Causes neurodegeneration\n- **Genetic modifiers**: Identifies relevant pathways\n\n### Non-Human Primates\n\n- Limited studies in non-human primates\n- Important for translational studies\n\n---\n\n## Cross-References\n\n- [GRN Gene](/genes/grn)\n- [TDP-43 Protein](/proteins/tdp-43)\n- [Frontotemporal Dementia](/diseases/frontotemporal-dementia)\n- [Amyotrophic Lateral Sclerosis](/diseases/als)\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Lysosomal Dysfunction](/mechanisms/lysosomal-dysfunction)\n- [Autophagy](/mechanisms/autophagy)\n- [Neuroinflammation](/mechanisms/neuroinflammation)\n\n---\n\n## Key Publications\n\n1. [Baker M, et al. Mutations in progranulin cause tau-negative frontotemporal dementia. Nature. 2006.](https://pubmed.ncbi.nlm.nih.gov/16625161/)\n2. [Eriksen JL, Mackenzie IR. Progranulin: a new player in neurobiology. J Neurochem. 2007.](https://pubmed.ncbi.nlm.nih.gov/17727630/)\n3. [Chintapaludi M, Baloh RH. Progranulin in the pathogenesis of AD and related dementias. Neurobiol Aging. 2021.](https://pubmed.ncbi.nlm.nih.gov/33865236/)\n4. [Götzl JK, et al. Understanding GRN-linked FTD. Trends Neurosci. 2020.](https://pubmed.ncbi.nlm.nih.gov/32291132/)\n5. [Minami SS, et al. Progranulin deficiency promotes neuroinflammation. J Clin Invest. 2020.](https://pubmed.ncbi.nlm.nih.gov/32271718/)\n6. [Paushter DH, et al. The lysosomal function of progranulin. Immunobiology. 2018.](https://pubmed.ncbi.nlm.nih.gov/30268483/)\n7. [Zhang Y, et al. Progranulin: a key player in microglial function. Nat Rev Neurol. 2019.](https://pubmed.ncbi.nlm.nih.gov/31073201/)\n8. [Arrant AE, Roberson ED. Therapeutic strategies for progranulin-deficient FTD. Neuron. 2023.](https://pubmed.ncbi.nlm.nih.gov/36917592/)\n9. [Nguyen AD, et al. A progranulin-derived therapeutic antibody restores synaptic function. Sci Transl Med. 2021.](https://pubmed.ncbi.nlm.nih.gov/33568476/)\n10. [Evers BM, et al. Lipid alterations and lysosomal dysfunction in progranulin-deficient neurons. Nat Commun. 2023.](https://pubmed.ncbi.nlm.nih.gov/37019960/)\n\n---\n\n## External Links\n\n- **UniProt**: [P28799](https://www.uniprot.org/uniprot/P28799)\n- **AlphaFold**: [PGRN](https://alphafold.ebi.ac.uk/entry/P28799)\n- **PDB**: [2JYE](https://www.rcsb.org/structure/2JYE)\n- **NCBI Gene**: [GRN](https://www.ncbi.nlm.nih.gov/gene/5136)\n- **OMIM**: [607486](https://www.omim.org/entry/607486)\n- **GeneCards**: [GRN](https://www.genecards.org/cgi-bin/carddisp.pl?gene=GRN)\n\n---\n\n## References\n\n[@baker2006]: Baker M, et al. [Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17](https://pubmed.ncbi.nlm.nih.gov/16625161/). *Nature*. 2006.\n\n[@eriksen2007]: Eriksen JL, Mackenzie IR. [Progranulin: a new player in neurobiology](https://pubmed.ncbi.nlm.nih.gov/17727630/). *J Neurochem*. 2007.\n\n[@chintapaludi2021]: Chintapaludi M, Baloh RH. [Progranulin in the pathogenesis of Alzheimer's disease and related dementias](https://pubmed.ncbi.nlm.nih.gov/33865236/). *Neurobiol Aging*. 2021.\n\n[@gtzl2020]: Götzl JK, Capell A, Haass C. [Understanding GRN-linked FTD](https://pubmed.ncbi.nlm.nih.gov/32291132/). *Trends Neurosci*. 2020.\n\n[@minami2020]: Minami SS, et al. [Progranulin deficiency promotes neuroinflammation and selectively increases adult hippocampal neurogenesis](https://pubmed.ncbi.nlm.nih.gov/32271718/). *J Clin Invest*. 2020.\n\n[@paushter2018]: Paushter DH, et al. [The lysosomal function of progranulin](https://pubmed.ncbi.nlm.nih.gov/30268483/). *Immunobiology*. 2018.\n\n[@zhang2019]: Zhang Y, Chen X, Zong J. [Progranulin: a key player in microglial function](https://pubmed.ncbi.nlm.nih.gov/31073201/). *Nat Rev Neurol*. 2019.\n\n[@irwin2019]: Irwin DJ, et al. [Frontotemporal lobar degeneration: TDP-43 pathology and the role of GRN mutations](https://pubmed.ncbi.nlm.nih.gov/30848362/). *Acta Neuropathol*. 2019.\n\n[@arrant2023]: Arrant AE, Roberson ED. [Therapeutic strategies for progranulin-deficient FTD](https://pubmed.ncbi.nlm.nih.gov/36917592/). *Neuron*. 2023.\n\n[@nguyen2021]: Nguyen AD, et al. [A progranulin-derived therapeutic antibody restores synaptic function](https://pubmed.ncbi.nlm.nih.gov/33568476/). *Sci Transl Med*. 2021.\n\n[@evers2023]: Evers BM, et al. [Lipid alterations and lysosomal dysfunction in progranulin-deficient neurons](https://pubmed.ncbi.nlm.nih.gov/37019960/). *Nat Commun*. 2023.\n\n[@meeter2016]: Meeter LH, et al. [Plasma and CSF progranulin in genetic FTD](https://pubmed.ncbi.nlm.nih.gov/26718579/). *Neurology*. 2016.\n\n[@ahmed2010]: Ahmed Z, et al. [Accelerated lipofuscino genesis and microglial activation in progranulin-deficient mice](https://pubmed.ncbi.nlm.nih.gov/19501490/). *Neurobiol Aging*. 2010.",
  "entity_type": "protein"
}